Gilead Sciences (GILD) Receives ‘Analyst’ Rating

Gilead Sciences (GILD) : 18 analysts are covering Gilead Sciences (GILD) and their average rating on the stock is 1.94, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Gilead Sciences (GILD) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 8 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Gilead Sciences (GILD) : The highest level Gilead Sciences (GILD) is projected to reach is $122 for the short term and the lowest estimate is at $91. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $108.75 and the possibility the share price can swing is $9.16.


Also, Jefferies upgrades its rating on Gilead Sciences (NASDAQ:GILD). Analysts at the Jefferies have a current rating of Buy on the shares. The shares were previously rated Hold. The rating by the firm was issued on September 6, 2016.

Gilead Sciences (NASDAQ:GILD): After opening at $77.75, the stock dipped to an intraday low of $77.27 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $79.2 and the buying power remained strong till the end. The stock closed at $78.84 for the day, a gain of 1.57% for the day session. The total traded volume was 10,138,588. The stocks close on the previous trading day was $77.62.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.